Regeneron is expanding its genomics efforts and operations, building upon its strengths in mouse genetics (VelociGene®; VelocImmune® and related technologies) and genetics-driven drug discovery and development (e.g. Interleukin-1 blocker rilonacept, FDA approved in 2008; PCSK9 antibody alirocumab, in Phase 3; and several other important pipeline medicines). Specific capabilities that have been built include large scale whole exome and whole genome sequencing projects, functional biology and mouse genetics for disease modeling, and translational research integrating genetics discovery research with Regeneron's growing pipeline development efforts. Along with others in industry and academia, Regeneron has long seen human genetics and genomics as essential platforms for facilitating and enabling drug discovery and development; we believe technological advances and other trends now make it possible to more fully realize this potential.

Goals for Regeneron's programs include target discovery, indication discovery, and patient-disease stratification through the use of human genetics and related genomic sciences. Regeneron’s interests encompass a breadth of different areas spanning Mendelian and family frameworks, large scale population genetics (both common and rare variants), and gene-gene interactions. The company will rely on its internal assets and technologies as well as continue to collaborate with investigators around the world in pursuing exciting genetics discovery projects. Regeneron has established major collaborations as foundational pieces of its genetics program. Regeneron is looking for talented and motivated individuals to join the company, complement internal teams and resources, and help lead these exciting programs and expanded efforts.

Click here to learn more about the Regeneron Genetics Center from the January 13, 2014 press release.

X

Locate Us

  • Corporate Headquarters
  • 777 Old Saw Mill River Road
  • Tarrytown, NY 10591
  • 914-847-7000

Get Social

X

Get Social

Regeneron Genetics Center

  • "This is such an exciting time for genomics and medicine. Bringing genetic information together with the medical record to discover new variants, genes, and pathways that can inform drug development has the potential to revolutionize healthcare, and deliver on some of the promise of genomic medicine. With this vision in mind, at the RGC we are building the first large-scale sequence-to-drug effort to contribute to the genomic revolution."

    - Jeffrey Reid Ph.D., Director Genome Informatics

  • "Regeneron's strong commitment to the success of this project, combined with its entrepreneurial spirit and well-established expertise in basic research and mouse genetics, form a foundation we feel will lead to significant advances in our understanding of the fundamental etiology of diseases, drug development, and, ultimately, in patient care."

    - John Overton Ph.D., Associate Director, Sequencing and Lab Operations

  • "The Regeneron Genetics Center is a one of a kind research engine committed to the pursuit of scientific excellence and the goal of uncovering genetics insights with groundbreaking impact on science and medicine. We are looking for talented and motivated leaders who share our commitment to science, are highly collaborative, and are guided by the highest of values and integrity. Come join us in our pursuit of tomorrow's breakthroughs and another chapter of exciting science at Regeneron."

    - Aris Baras M.D., Director R&D Initiatives, Deputy Head RGC

Stay Connected

Take the first step in taking your career to the next level. Sign up here for regular job alerts that match your talents and skills!

Advertisement